Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Geron Corporation

Geron Corporation (GERN) Stock Overview

Explore Geron Corporation’s financial performance, market position, analyst ratings, and future outlook.

GERN●NASDAQ
HealthcareBiotechnology
$0.91
$0.24(20.82%)
U.S. Market is Open · 14:36

Geron Corporation (GERN)

Meyka AI Score

Z

Key Financials

Market Cap622.2M
P/E Ratio-9.65
EPS (TTM)$-0.09
ROE-0.30%
Fundamental Analysis

AI Price Forecasts

1 Month$1.08
3 Months$1.43
1 Year Target$0.32

GERN Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Geron Corporation (NASDAQ: GERN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Geron Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GERN on the NASDAQ shows an RSI of 25.59, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $0.32 for the NASDAQ listing.

Key metrics behind Geron Corporation's NASDAQ-traded stock include a P/E ratio of -9.65 and a market capitalization of 622.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of GERN on the NASDAQ.

Price Performance (NASDAQ: GERN)

1-Day Change
-15.78%
5-Day Change
-15.78%
1-Month Change
-22.52%
3-Month Change
-33.21%
6-Month Change
-35.86%
Year-to-Date (YTD) Change
-26.63%
1-Year Change
-24.34%
3-Year Change
-49.29%
5-Year Change
-38.31%
All-Time (Max) Change
-86.79%

Contact Information

https://www.geron.com
650 473 7700
919 East Hillsdale Boulevard, Foster City, CA, 94404

Company Facts

2,580 Employees
IPO DateJul 31, 1996
CountryUS
Actively Trading

Frequently Asked Questions